跳至主要内容
临床试验/EUCTR2005-005946-38-DE
EUCTR2005-005946-38-DE进行中(未招募)不适用

A DOUBLE-BLIND INTER-INDIVIDUAL COMPARISON OF IOMEPROL 300 AND IOMEPROL 400 IN MULTI-DETECTOR CT ANGIOGRAPHY (MDCTA) OF PERIPHERAL ARTERIES

Bracco ALTANA Pharma GmbH0 个研究点目标入组 64 人开始时间: 2005年12月27日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
64

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Indication for Computed Tomographic Angiography (CTA)
  • - Patient is adult (age = 18 years), conscious and co-operative
  • - Written Informed Consent to participate in the study
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Known aortic aneurysm
  • - Major endoprosthesis, which could bias the diagnostic accuracy of MDCTA
  • - Hyperthyroidism (TSH below 0.3 mU/L)
  • - Renal insufficiency (serum creatinine > 1.5 mg/dL)
  • - Hypersensitivity to iodinated contrast media or significant allergic disposition
  • - Insulin-dependent diabetes mellitus, or metformin medication (discontinuation for 48 h enables CT examination of patients with normal renal function)
  • - Known pheochromocytoma or paraproteinaemia
  • - Acute stroke or cerebral oedema
  • - Known Epilepsy; currently active
  • - Planned radioactive iodine therapy
  • - Participation in a clinical trial within the past 30 days
  • - Previous participation in this clinical trial
  • - Alcohol or drug abuse
  • - Patient is female and pregnant or nursing
  • - Patient is female and the possibility of pregnancy cannot be excluded from one of the following points:
  • · surgical sterilization (method has to be recorded on medical history form)
  • · confirmed post-menopausal (with minimum 1-year history without menstruation)
  • · negative pregnancy test (confirmed via ß-HCG measurement)
  • - Patient is institutionalized by law
  • - Circumstances that would significantly decrease the chance of obtaining reliable data or of achieving the study objectives according to the Investigator’s final opinion
  • - Peripheral vein conditions, which would not allow for the required fast administration of contrast agents (18 gauge needle)

研究者

发起方
Bracco ALTANA Pharma GmbH

相似试验

进行中(未招募)
不适用
A DOUBLE-BLIND INTER-INDIVIDUAL COMPARISON OF IOMEPROL 300 AND IOMEPROL 400 IN THE ASSESSMENT OF PERFUSION CT OF ADVANCED RENAL CARCINOMA - Perfusion CT of Renal Carcinoma
EUCTR2006-002858-29-DEBracco Imaging Deutschland GmbH60
招募中
2 期
Prospective intra-individual comparison of the mpMRI versus 68Ga-PSMA11 PET/MRI in a blinded read to evaluate diagnostic accuracy in patients with prostate cancerD011471Prostate Cancer
JPRN-jRCTs022220021Kojima Yoshiyuki152
进行中(未招募)
不适用
Intra-individual randomized comparison of the efficacy of two botulinum toxins type A on moderate to severe forehead wrinkles after one injectio
EUCTR2009-010338-23-DEGALDERMA Research & Development30
招募中
不适用
A prospective open intra-individual comparative cohort study to investigate the performance characteristics of Gadoxetic Acid (Primovist®)-enhanced MRI and Ultrasonography for the surveillance of early stage HCC in patients with liver cirrhosis at high-riskDiseases of the digestive system
KCT0000277Asan Medical Center423
进行中(未招募)
不适用
etude comparative randomisee intra-individuelle de l'efficacite du traitement d'hidradenite suppuree ou maladie de verneuil par injections sous cutanee de toxine botulinique versus placebo - verneuil2006’hidradénite suppurée est une affection des glandes sudorales apocrines. Les glandes apocrines sont sous la dépendance des terminaisons nerveuses orthosympathiques . Le mécanisme d’action de la toxine botulinique est le blocage de la transmission cholinergique des glandes sudorales . Nous avons rapporter l’efficacité de la toxine botulinique pour le traitement de la maladie de Verneuil et nous souhaitons vérifier l’efficacité de ce traitement par une étude en double aveugle
EUCTR2007-000534-39-FRacep16